COLORADO SPRINGS, Colo.,
Dec. 30, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, "is prepared to put the pedal to the metal" in
2015, in the words of Raymond C.
Dabney, its Director, President & CEO and
Co-Founder.
"We really want to offer a heartfelt 'thank you' to our
investors and supporters for a great year in 2014," said Dabney.
"We have come a long way and we believe we are ready to move to the
next level in 2015, in terms of commercialization of our products,
increased levels of public awareness and our ability to help
address serious health issues not just in the U.S., but also in
Africa, where we are becoming more
active."
In Africa, Dabney, along with
CBIS Senior Scientific Advisor Dr. Roscoe
M. Moore, Jr., has initiated a partnership between CBIS and
the Constituency for Africa (CFA)
to help improve healthcare and health-related education
infrastructure. Founded in 1990, the CFA has emerged as a leading
organization for mobilizing public and private support for
Africa in Washington, DC.
"Africa is just one example of
how we're firing on all cylinders," Dabney said. "We think 2015 is
going to be a special year."
In California, the company is
in the final stages of preparation to launch new products such as
extracts, oils, tinctures, tablets, and creams, thanks to the
renegotiation of its agreement with Apothecary Genetics Investments
LLC. The agreement enables Cannabis Science to purchase and license
two northern California production
farms with a combined total of 51 acres. The purchase included all
related equipment for cannabis cultivation and production for the
state's substantial medical cannabis market and gives Apothecary
Genetics the right to sell Cannabis Science formulations throughout
the State of California.
In Spain, the company is moving
into 2nd stage cannabinoid production and is on track to deliver
extensive data on CBD and THC levels, along with treatment regimes
for many of its targeted ailments. "Our year-round growing
capabilities give us the ability to meet the growing demand based
on the number of delivery methods we are developing for various
critical ailments," Mario S. Lap, Director and President of
European Operations, said when the Spanish news was announced.
"We will be providing our formulation and developing scalability
and portability for our pre-clinical programs that will target GMP
production requirements. We're also working with and assisting in
the creation of other patient groups in Spain and other countries to use formulations
we develop," said Chad Johnson,
Director and Chief Operating Officer. "These are only a few
of our international operations planned to be rolled out in the New
Year."
About Cannabis Science, Inc. Cannabis Science,
Inc., takes advantage of its unique understanding of metabolic
processes to provide novel treatment approaches to a number of
illnesses for which current treatments and understanding remain
unsatisfactory. Cannabinoids have an extensive history dating back
thousands of years, and currently, there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal
characterization, and clinical research to develop, produce, and
commercialize novel therapeutic approaches for the treatment for
illnesses caused by infections as well as for age-related illness.
Our initial focus is on skin cancers and neurological
conditions.
Forward-Looking Statements This Press Release
includes forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Act of 1934. A statement containing words such as "anticipate,"
"seek," intend," "believe," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science,
Inc., does not undertake any duty nor does it intend to update the
results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director,
President & CEO, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director,
COO, & General Counsel
www.cannabisscience.com info@cannabisscience.com
Tel: 1.888.777.0658
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-ready-for-a-prosperous-and-healthy-new-year-the-best-is-yet-to-come-300014621.html
SOURCE Cannabis Science, Inc.